These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 35619721

  • 61. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome.
    Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Staniforth SJ, Holmes LV, Ward R, Morgan L, Goodship TH, Marchbank KJ.
    Blood; 2010 Jan 14; 115(2):379-87. PubMed ID: 19861685
    [Abstract] [Full Text] [Related]

  • 62. A Novel Homozygous In-Frame Deletion in Complement Factor 3 Underlies Early-Onset Autosomal Recessive Atypical Hemolytic Uremic Syndrome - Case Report.
    Pollack S, Eisenstein I, Mory A, Paperna T, Ofir A, Baris-Feldman H, Weiss K, Veszeli N, Csuka D, Shemer R, Glaser F, Prohászka Z, Magen D.
    Front Immunol; 2021 Jan 14; 12():608604. PubMed ID: 34248927
    [Abstract] [Full Text] [Related]

  • 63. A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation.
    Valoti E, Alberti M, Tortajada A, Garcia-Fernandez J, Gastoldi S, Besso L, Bresin E, Remuzzi G, Rodriguez de Cordoba S, Noris M.
    J Am Soc Nephrol; 2015 Jan 14; 26(1):209-19. PubMed ID: 24904082
    [Abstract] [Full Text] [Related]

  • 64. CFH and CFHR structural variants in atypical Hemolytic Uremic Syndrome: Prevalence, genomic characterization and impact on outcome.
    Piras R, Valoti E, Alberti M, Bresin E, Mele C, Breno M, Liguori L, Donadelli R, Rigoldi M, Benigni A, Remuzzi G, Noris M.
    Front Immunol; 2022 Jan 14; 13():1011580. PubMed ID: 36793547
    [Abstract] [Full Text] [Related]

  • 65. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases.
    Blanc C, Togarsimalemath SK, Chauvet S, Le Quintrec M, Moulin B, Buchler M, Jokiranta TS, Roumenina LT, Fremeaux-Bacchi V, Dragon-Durey MA.
    J Immunol; 2015 Jun 01; 194(11):5129-38. PubMed ID: 25917093
    [Abstract] [Full Text] [Related]

  • 66. Blockade of the Terminal Complement Cascade Using Ravulizumab in a Pediatric Patient With Anti-complement Factor H Autoantibody-Associated aHUS: A Case Report and Literature Review.
    Wu X, Szarzanowicz A, Garba A, Schaefer B, Waz WR.
    Cureus; 2021 Nov 01; 13(11):e19476. PubMed ID: 34912617
    [Abstract] [Full Text] [Related]

  • 67. Atypical hemolytic uremic syndrome.
    Loirat C, Frémeaux-Bacchi V.
    Orphanet J Rare Dis; 2011 Sep 08; 6():60. PubMed ID: 21902819
    [Abstract] [Full Text] [Related]

  • 68. Contribution of functional and quantitative genetic variants of Complement Factor H and Factor H-Related (FHR) proteins on renal pathology.
    Gómez Delgado I, Sánchez-Corral P.
    Nefrologia (Engl Ed); 2022 Sep 08; 42(3):280-289. PubMed ID: 36154806
    [Abstract] [Full Text] [Related]

  • 69. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome.
    Bu F, Maga T, Meyer NC, Wang K, Thomas CP, Nester CM, Smith RJ.
    J Am Soc Nephrol; 2014 Jan 08; 25(1):55-64. PubMed ID: 24029428
    [Abstract] [Full Text] [Related]

  • 70. The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models.
    Saunders RE, Abarrategui-Garrido C, Frémeaux-Bacchi V, Goicoechea de Jorge E, Goodship TH, López Trascasa M, Noris M, Ponce Castro IM, Remuzzi G, Rodríguez de Córdoba S, Sánchez-Corral P, Skerka C, Zipfel PF, Perkins SJ.
    Hum Mutat; 2007 Mar 08; 28(3):222-34. PubMed ID: 17089378
    [Abstract] [Full Text] [Related]

  • 71. Genetics of atypical hemolytic uremic syndrome (aHUS).
    Rodríguez de Córdoba S, Hidalgo MS, Pinto S, Tortajada A.
    Semin Thromb Hemost; 2014 Jun 08; 40(4):422-30. PubMed ID: 24799305
    [Abstract] [Full Text] [Related]

  • 72. An ex vivo test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndrome.
    Gastoldi S, Aiello S, Galbusera M, Breno M, Alberti M, Bresin E, Mele C, Piras R, Liguori L, Santarsiero D, Benigni A, Remuzzi G, Noris M.
    Front Immunol; 2023 Jun 08; 14():1112257. PubMed ID: 36845135
    [Abstract] [Full Text] [Related]

  • 73. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency.
    Lee BH, Kwak SH, Shin JI, Lee SH, Choi HJ, Kang HG, Ha IS, Lee JS, Dragon-Durey MA, Choi Y, Cheong HI.
    Pediatr Res; 2009 Sep 08; 66(3):336-40. PubMed ID: 19531976
    [Abstract] [Full Text] [Related]

  • 74. [Comparative characteristics of the complement system in patients with C3-glomerulopathy and atypical hemolytic uremic syndrome of chronic course who suffered an acute episode of thrombotic microangiopathy].
    Yurova VA, Kozlovskaya NL, Bobrova LA, Kozlov LV, Andina SS, Demyanova KA.
    Ter Arkh; 2023 Aug 17; 95(6):475-480. PubMed ID: 38158966
    [Abstract] [Full Text] [Related]

  • 75. Genotypic analysis of a large cohort of patients with suspected atypical hemolytic uremic syndrome.
    Connaughton DM, Bhai P, Isenring P, Mahdi M, Sadikovic B, Schenkel LC.
    J Mol Med (Berl); 2023 Aug 17; 101(8):1029-1040. PubMed ID: 37466676
    [Abstract] [Full Text] [Related]

  • 76. Mutations in atypical hemolytic uremic syndrome provide evidence for the role of calcium in complement factor I.
    Java A, Atkinson J, Hu Z, Pozzi N.
    Blood; 2023 Aug 10; 142(6):607-610. PubMed ID: 37363824
    [Abstract] [Full Text] [Related]

  • 77. Selective Binding of Heparin/Heparan Sulfate Oligosaccharides to Factor H and Factor H-Related Proteins: Therapeutic Potential for C3 Glomerulopathies.
    Loeven MA, Maciej-Hulme ML, Yanginlar C, Hubers MC, Kellenbach E, de Graaf M, van Kuppevelt TH, Wetzels J, Rabelink TJ, Smith RJH, van der Vlag J.
    Front Immunol; 2021 Aug 10; 12():676662. PubMed ID: 34489931
    [Abstract] [Full Text] [Related]

  • 78. An extremely rare splice site mutation in the gene encoding complement factor I in a patient with atypical hemolytic uremic syndrome.
    Ipe TS, Lim J, Reyes MA, Ero M, Leveque C, Lewis B, Kain J.
    J Clin Apher; 2017 Dec 10; 32(6):584-588. PubMed ID: 28455885
    [Abstract] [Full Text] [Related]

  • 79. Partial Complement Factor H Deficiency Associates with C3 Glomerulopathy and Thrombotic Microangiopathy.
    Vernon KA, Ruseva MM, Cook HT, Botto M, Malik TH, Pickering MC.
    J Am Soc Nephrol; 2016 May 10; 27(5):1334-42. PubMed ID: 26374608
    [Abstract] [Full Text] [Related]

  • 80. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
    Michels MAHM, van de Kar NCAJ, van Kraaij SAW, Sarlea SA, Gracchi V, Engels FAPT, Dorresteijn EM, van der Deure J, Duineveld C, Wetzels JFM, van den Heuvel LPWJ, Volokhina EB.
    Front Immunol; 2021 May 10; 12():715704. PubMed ID: 34456924
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.